Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

John M. Goldman

Showing results (41-50 of 96) with videos related to

Pageof 10
Sort By:
International Journal of Cancer|July 8, 2003
Tartrate-resistant acid phosphatase isoform 5b: a novel serum marker for monitoring bone disease in multiple myelomaEvangelos Terpos, Josu de la Fuente, Richard Szydlo, et al.
Experimental Hematology|December 17, 2002
A role for the Fas/Fas ligand apoptotic pathway in regulating myeloid progenitor cell kineticsFaris Q B Alenzi, Stephen B Marley, John L Lewis, et al.
Blood|March 16, 2002
Factors affecting duration of survival after onset of blastic transformation of chronic myeloid leukemiaJyoti Wadhwa, Richard M Szydlo, Jane F Apperley, et al.
Blood|April 12, 2003
Soluble receptor activator of nuclear factor kappaB ligand-osteoprotegerin ratio predicts survival in multiple myeloma: proposal for a novel prognostic indexEvangelos Terpos, Richard Szydlo, Jane F Apperley, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 10, 2011
BCR-ABL transcript dynamics support the hypothesis that leukemic stem cells are reduced during imatinib treatmentAndrew M Stein, Dean Bottino, Vijay Modur, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 10, 2010
Relapse and late mortality in 5-year survivors of myeloablative allogeneic hematopoietic cell transplantation for chronic myeloid leukemia in first chronic phaseJohn M Goldman, Navneet S Majhail, John P Klein, et al.
Leukemia Research|July 31, 2009
BCR-ABL transcripts are not detected in cord blood or the peripheral blood of the newborn child whose mother developed chronic myeloid leukemia while pregnantOphira Salomon, Tali Tohami, Luba Trakhtenbrot, et al.
Cancer Research|October 6, 2005
Bcr-Abl expression levels determine the rate of development of resistance to imatinib mesylate in chronic myeloid leukemiaDavid J Barnes, Danai Palaiologou, Eleni Panousopoulou, et al.
British Journal of Haematology|April 27, 2007
Impact of imatinib therapy on the use of allogeneic haematopoietic progenitor cell transplantation for the treatment of chronic myeloid leukaemiaSergio A Giralt, Mukta Arora, John M Goldman, et al.
British Journal of Haematology|October 3, 2002
Mutation in the ATP-binding site of BCR-ABL in a patient with chronic myeloid leukaemia with increasing resistance to STI571Christophe Barthe, Marie-Josée Gharbi, Valérie Lagarde, et al.
Pageof 10

Showing results (41-50 of 96) with videos related to

Sort By:
Pageof 10
International Journal of Cancer|July 8, 2003
Tartrate-resistant acid phosphatase isoform 5b: a novel serum marker for monitoring bone disease in multiple myelomaEvangelos Terpos, Josu de la Fuente, Richard Szydlo, et al.
Experimental Hematology|December 17, 2002
A role for the Fas/Fas ligand apoptotic pathway in regulating myeloid progenitor cell kineticsFaris Q B Alenzi, Stephen B Marley, John L Lewis, et al.
Blood|March 16, 2002
Factors affecting duration of survival after onset of blastic transformation of chronic myeloid leukemiaJyoti Wadhwa, Richard M Szydlo, Jane F Apperley, et al.
Blood|April 12, 2003
Soluble receptor activator of nuclear factor kappaB ligand-osteoprotegerin ratio predicts survival in multiple myeloma: proposal for a novel prognostic indexEvangelos Terpos, Richard Szydlo, Jane F Apperley, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 10, 2011
BCR-ABL transcript dynamics support the hypothesis that leukemic stem cells are reduced during imatinib treatmentAndrew M Stein, Dean Bottino, Vijay Modur, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 10, 2010
Relapse and late mortality in 5-year survivors of myeloablative allogeneic hematopoietic cell transplantation for chronic myeloid leukemia in first chronic phaseJohn M Goldman, Navneet S Majhail, John P Klein, et al.
Leukemia Research|July 31, 2009
BCR-ABL transcripts are not detected in cord blood or the peripheral blood of the newborn child whose mother developed chronic myeloid leukemia while pregnantOphira Salomon, Tali Tohami, Luba Trakhtenbrot, et al.
Cancer Research|October 6, 2005
Bcr-Abl expression levels determine the rate of development of resistance to imatinib mesylate in chronic myeloid leukemiaDavid J Barnes, Danai Palaiologou, Eleni Panousopoulou, et al.
British Journal of Haematology|April 27, 2007
Impact of imatinib therapy on the use of allogeneic haematopoietic progenitor cell transplantation for the treatment of chronic myeloid leukaemiaSergio A Giralt, Mukta Arora, John M Goldman, et al.
British Journal of Haematology|October 3, 2002
Mutation in the ATP-binding site of BCR-ABL in a patient with chronic myeloid leukaemia with increasing resistance to STI571Christophe Barthe, Marie-Josée Gharbi, Valérie Lagarde, et al.
Pageof 10